Dimensional Fund Advisors LP Raises Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Dimensional Fund Advisors LP increased its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 5.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,991,702 shares of the company's stock after purchasing an additional 278,653 shares during the period. Dimensional Fund Advisors LP owned 1.61% of Amneal Pharmaceuticals worth $39,531,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Franklin Resources Inc. lifted its position in shares of Amneal Pharmaceuticals by 4.9% in the third quarter. Franklin Resources Inc. now owns 89,887 shares of the company's stock valued at $778,000 after acquiring an additional 4,178 shares in the last quarter. Arizona State Retirement System boosted its position in Amneal Pharmaceuticals by 13.6% during the fourth quarter. Arizona State Retirement System now owns 40,401 shares of the company's stock worth $320,000 after acquiring an additional 4,851 shares during the last quarter. Alliancebernstein L.P. lifted its stake in Amneal Pharmaceuticals by 2.5% in the 4th quarter. Alliancebernstein L.P. now owns 200,246 shares of the company's stock worth $1,586,000 after purchasing an additional 4,927 shares in the last quarter. Globeflex Capital L P lifted its holdings in Amneal Pharmaceuticals by 3.8% in the fourth quarter. Globeflex Capital L P now owns 144,439 shares of the company's stock valued at $1,144,000 after acquiring an additional 5,245 shares during the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its position in Amneal Pharmaceuticals by 13.6% in the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 46,240 shares of the company's stock valued at $366,000 after purchasing an additional 5,523 shares during the period. 31.82% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently issued reports on AMRX. Barclays upped their price objective on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a report on Monday, March 3rd. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and increased their price target for the stock from $9.00 to $12.00 in a research report on Monday, February 24th. Finally, StockNews.com raised shares of Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Monday, May 5th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $11.50.

Amneal Pharmaceuticals Price Performance

Shares of AMRX stock traded down $0.04 during trading hours on Friday, reaching $7.42. 1,777,488 shares of the stock were exchanged, compared to its average volume of 1,434,572. Amneal Pharmaceuticals, Inc. has a 12-month low of $6.29 and a 12-month high of $9.48. The business's fifty day moving average is $7.90 and its two-hundred day moving average is $8.13. The firm has a market capitalization of $2.30 billion, a P/E ratio of -10.91 and a beta of 1.17.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings data on Friday, May 2nd. The company reported $0.19 earnings per share for the quarter, beating analysts' consensus estimates of $0.14 by $0.05. The business had revenue of $695.42 million for the quarter, compared to analyst estimates of $714.78 million. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. As a group, equities research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Insider Transactions at Amneal Pharmaceuticals

In other news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the company's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $8.35, for a total value of $41,750,000.00. Following the completion of the transaction, the insider now owns 48,578,209 shares in the company, valued at approximately $405,628,045.15. This represents a 9.33 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Gautam Patel sold 80,000 shares of Amneal Pharmaceuticals stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.90, for a total transaction of $712,000.00. Following the sale, the director now owns 1,808,886 shares in the company, valued at $16,099,085.40. This represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 26.56% of the company's stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.